BIOMAT Database Logo BIOMAT Database Logo

Quantitative analysis of AML1/ETO transcripts in peripheral blood stem cell harvests from patients with t(8;21) acute myelogenous leukaemia. 1995

T Miyamoto, and K Nagafuji, and M Harada, and T Eto, and T Fujisaki, and A Kubota, and K Akashi, and S Mizuno, and K Takenaka, and T Kanaji
First Department of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka, Japan.

Peripheral blood stem cells (PBSC) have been used increasingly for haemopoietic reconstitution after marrow-ablative chemotherapy in patients with acute leukaemia because of the possibility that there is a lower risk of leukaemic contamination. We have developed a titration assay using a competitive reverse transcriptase polymerase chain reaction (RT-PCR) which is able to estimate the number of AML1/ETO transcripts so that minimal residual disease (MRD) can be monitored quantitatively in patients with t(8;21) acute myelogenous leukaemia (AML). Using a qualitative RT-PCR method, AML1/ETO transcripts could be detected in all samples from 15 first PBSC harvests and 11 second PBSC harvests obtained from 15 patients with t(8;21) AML. With our competitive RT-PCR assay, the number of AML1/ETO transcripts was found to be lower in the second PBSC harvest than that in the first in every individual. Furthermore, MRD in PBSC harvests was less than that in the corresponding bone marrow obtained on the day of PBSC collection in the individual patients studied. In 10 patients who received autologous blood stem cell transplantation (ABSCT), we could not find a relationship between the number of AML1/ETO transcripts in the infused PBSC harvests and the clinical outcome after ABSCT. The present study clearly indicates that although PBSC harvests collected after consolidation chemotherapy are contaminated by leukaemic cells, the degree of leukaemic contamination may decrease as chemotherapy is repeated. The mobilization of PBSC by repeated chemotherapy may provide an advantageous source of haemopoietic stem cells for ABSCT.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D001853 Bone Marrow The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D002891 Chromosomes, Human, Pair 21 A specific pair of GROUP G CHROMOSOMES of the human chromosome classification. Chromosome 21
D002898 Chromosomes, Human, Pair 8 A specific pair of GROUP C CHROMOSOMES of the human chromosome classification. Chromosome 8
D004268 DNA-Binding Proteins Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases. DNA Helix Destabilizing Proteins,DNA-Binding Protein,Single-Stranded DNA Binding Proteins,DNA Binding Protein,DNA Single-Stranded Binding Protein,SS DNA BP,Single-Stranded DNA-Binding Protein,Binding Protein, DNA,DNA Binding Proteins,DNA Single Stranded Binding Protein,DNA-Binding Protein, Single-Stranded,Protein, DNA-Binding,Single Stranded DNA Binding Protein,Single Stranded DNA Binding Proteins
D005260 Female Females

Related Publications

T Miyamoto, and K Nagafuji, and M Harada, and T Eto, and T Fujisaki, and A Kubota, and K Akashi, and S Mizuno, and K Takenaka, and T Kanaji
Molecular diversity in AML1/ETO fusion transcripts in patients with t(8;21) positive acute myeloid leukaemia.
October 1994, Leukemia,
T Miyamoto, and K Nagafuji, and M Harada, and T Eto, and T Fujisaki, and A Kubota, and K Akashi, and S Mizuno, and K Takenaka, and T Kanaji
AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation.
June 2000, Proceedings of the National Academy of Sciences of the United States of America,
T Miyamoto, and K Nagafuji, and M Harada, and T Eto, and T Fujisaki, and A Kubota, and K Akashi, and S Mizuno, and K Takenaka, and T Kanaji
Detection of AML1/ETO fusion transcripts in patients with t(8;21) acute myeloid leukemia after allogeneic bone marrow transplantation or peripheral blood progenitor cell transplantation.
October 1997, Blood,
T Miyamoto, and K Nagafuji, and M Harada, and T Eto, and T Fujisaki, and A Kubota, and K Akashi, and S Mizuno, and K Takenaka, and T Kanaji
t(8;21;14)(q22;q22;q24) is a novel variant of t(8;21) with chimeric transcripts of AML1-ETO in acute myelogenous leukemia.
January 2002, Cancer genetics and cytogenetics,
T Miyamoto, and K Nagafuji, and M Harada, and T Eto, and T Fujisaki, and A Kubota, and K Akashi, and S Mizuno, and K Takenaka, and T Kanaji
Characterization of the ETO and AML1-ETO proteins involved in 8;21 translocation in acute myelogenous leukemia.
April 1998, European journal of haematology,
T Miyamoto, and K Nagafuji, and M Harada, and T Eto, and T Fujisaki, and A Kubota, and K Akashi, and S Mizuno, and K Takenaka, and T Kanaji
Disappearance of AML1-MTG8(ETO) fusion transcript in acute myeloid leukaemia patients with t(8;21) in long-term remission.
December 1995, British journal of haematology,
T Miyamoto, and K Nagafuji, and M Harada, and T Eto, and T Fujisaki, and A Kubota, and K Akashi, and S Mizuno, and K Takenaka, and T Kanaji
[Early relapse after peripheral blood stem cell transplantation in acute myelogenous leukemia with t(8;21)].
October 1995, [Rinsho ketsueki] The Japanese journal of clinical hematology,
T Miyamoto, and K Nagafuji, and M Harada, and T Eto, and T Fujisaki, and A Kubota, and K Akashi, and S Mizuno, and K Takenaka, and T Kanaji
Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)/AML1-ETO.
September 2006, British journal of haematology,
T Miyamoto, and K Nagafuji, and M Harada, and T Eto, and T Fujisaki, and A Kubota, and K Akashi, and S Mizuno, and K Takenaka, and T Kanaji
Detection of the AML1/ETO fusion transcript in the t(8;21) masked translocation in acute myelogenous leukemia.
October 1993, Cancer research,
T Miyamoto, and K Nagafuji, and M Harada, and T Eto, and T Fujisaki, and A Kubota, and K Akashi, and S Mizuno, and K Takenaka, and T Kanaji
[Monitoring AML1-ETO mRNA levels by real-time quantitative RT-PCR in t(8;21) acute myeloid leukemia patients after hematopoietic stem cell transplantation].
October 2008, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
Copied contents to your clipboard!